Third-party testimony could turn tide in US FTC’s challenge of Edwards-JenaValve

Third-party testimony piecing together the market for transcatheter aortic valve replacement devices in the United States, much of which was sealed during trial, could be key in the US Federal Trade...

Already a subscriber? Click here to view full article